AIM ImmunoTech
16 hedge funds and large institutions have $434K invested in AIM ImmunoTech in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
23% more funds holding
Funds holding: 13 → 16 (+3)
3% more capital invested
Capital invested by funds: $420K → $434K (+$14K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$25.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$15.8K |
| 3 |
VF
Virtu Financial
New York
|
+$12.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.44K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$61.8K |
| 2 |
Renaissance Technologies
New York
|
-$8.63K |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$1.44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $160K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $102K | -$61.8K | -43 | -39% |
|
|
TSS
3
Two Sigma Securities
New York
| $28K | +$25.9K | +18 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $25K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $21K | +$12.9K | +9 | +180% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $18K | +$1.44K | +1 | +9% |
|
|
7
Citadel Advisors
Miami,
Florida
| $16K | +$15.8K | +11 | New |
|
8
Creative Planning
Overland Park,
Kansas
| $14K | – | – | – |
|
9
Northern Trust
Chicago,
Illinois
| $11K | – | – | – |
|
|
10
Renaissance Technologies
New York
| $9K | -$8.63K | -6 | -50% |
|
|
GC
11
Guggenheim Capital
Chicago,
Illinois
| $7K | -$1.44K | -1 | -20% |
|
12
Wells Fargo
San Francisco,
California
| $7K | – | – | – |
|
13
Bank of New York Mellon
New York
| $5K | – | – | – |
|
|
OAM
14
Occidental Asset Management
Burlingame,
California
| $5K | – | – | – |
|
|
WPW
15
Waldron Private Wealth
Bridgeville,
Pennsylvania
| $3K | – | – | – |
|
|
16
UBS Group
Zurich,
Switzerland
| $3K | +$1.44K | +1 | New |
|
AIM Hedge Fund Activity: Q4 2017 in Review
16 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2017, worth a combined $434K — up 3.3% from $420K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new AIM positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $25.9K. The largest seller was Vanguard Group, cutting an estimated $61.8K.
- 16 institutional investors held AIM ImmunoTech (AIM) as of Q4 2017, up from 13 in Q3 2017.
- Funds reported $434K of AIM ImmunoTech stock for Q4 2017, up 3.3% quarter-over-quarter.
- 3 funds opened new AIM ImmunoTech positions in Q4 2017 and 0 closed out, a net change of +3 holders.
- The largest AIM ImmunoTech buyer in Q4 2017 was Two Sigma Securities, an estimated $25.9K added.
- The largest AIM ImmunoTech seller in Q4 2017 was Vanguard Group, an estimated $61.8K sold.
Based on aggregated 13F filings for Q4 2017.